Prevalence of Dihydrofolate reductase gene mutations in *Plasmodium falciparum* isolate from pregnant women in Nigeria

Olusola Ojurongbe,^{1,2} Bukola D Tijani,³
Adegboyega A. Fawole,⁴

Oluwaseyi A. Adeyeba,¹ Juergen F. Kun²

¹Department of Medical Microbiology and Parasitology, Ladoke Akintola University of Technology, Nigeria; ²Institute of Tropical Medicine, University of

Tuebingen, Germany; ³Department of Medical Microbiology and Parasitology, University of Ilorin Teaching Hospital;

⁴Department of Obstetrics and Gynecology, University of Ilorin Teaching Hospital, Nigeria

Abstract

We assessed the prevalence of *Plasmodium falciparum* and the frequency of the dhfr triple mutation that is associated with antifolate drug resistance among *P. falciparum* isolates obtained from pregnant women in Ilorin, Nigeria. The study included 179 women in the second and third trimester of pregnancy who have been exposed to intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine. Thick and thin blood films and PCR were used for malaria parasite detection. Blood group and hemoglobin concentration were also determined. Mutations in *P. falciparum* dhfr were analyzed by sequencing DNA obtained from blood spots on filter paper. Prevalence of *P. falciparum* in the population (PCR corrected) was 44.1% (79/179) with 66.7% and 33.3% in the second and third trimester, respectively. Primigravidae (51.3%) were more infected than multigravidae (48.7%) but the difference was not statistically significant. Women in blood group A had the highest *P. falciparum* malaria infection (30.8%). The mean hemoglobin concentration was lower among those infected with malaria parasite. Also, more women with the malaria parasite (38.4%) had anemia compare to those without (21.4%). The prevalence of the *P. falciparum* dhfr mutant alleles was 64.1%, 61.5%, 38.5%, and 12.8% for I51, R59, N108 and T108, respectively. None of the samples had the L164 mutation. The combined triple dhfr mutation (51 + 59 + 108) in the population was 17.9% (7 of 39). Also, the prevalence of the triple mutant alleles was not significantly associated to the number of doses of SP taken by the women. These findings highlight the need for a regular assessment of IPTp/SP efficacy, and evaluation of possible alternative drugs.

Introduction

In all endemic areas the risk, frequency and severity of malaria infection are greater in pregnant women than in the same women before pregnancy or in their non-pregnant counterparts. Regardless of the pre-pregnancy level of immunity against malaria, clinical consequences of pregnancy-associated malaria include maternal anemia, low newborn birth weight (LBW), pre-term delivery, and increased prenatal morbidity.¹

Prevention of malaria in pregnancy remains a major public health challenge and a priority for the Roll Back Malaria (RBM) Partnership. Methods of malaria prevention in pregnancy changed from a weekly or bimonthly chemoprophylaxis to intermittent preventive treatment (IPTp) and insecticide-treated bed nets (ITNs) at the beginning of the 21st century.² Sulfadoxine-pyrimethamine (SP) is the drug currently recommended for IPTp strategy.² It has a good safety profile and remains a good option in endemic areas of Africa.³ IPTp-SP is used to treat pregnant women, regardless of their malaria infection status, with spaced therapeutic doses (2-3 doses) during the second and third trimesters of pregnancy.⁴

Nigeria adopted the IPTp strategy in 2005 and the current National Malaria Treatment Guideline and Policy in Nigeria recommends SP as the drug of choice for IPTp and quinine for treatment of clinical malaria in all trimesters. Artemisinin based combination therapy (ACT) is considered a safe second-line agent in the second and third trimesters and may be used in the first trimester in cases in which there are no suitable alternatives.⁵ IPTp-SP has been shown to reduce the risk of maternal anemia, placental parasitemia and low birth weight.^{6,7} The ongoing use of SP, either in treatment of uncomplicated malaria or as a method of malaria control by intermittent preventive treatment, makes it important to constantly study SP resistance and the way resistance spreads in populations. The resistance against the pyrimethamine component of the SP combination occurs due to multiple key mutations in the dihydrofolate reductase (dhfr) gene of the parasite. The first mutation to appear is serine to asparagine at codon 108 of the dhfr (S108N), followed by asparagine to isoleucine at codon 51 (N51I) and cysteine to arginine at codon 59 (C59R), leading to triple mutation-108N + 51I + 59R.⁸ The mutations in the dihydropteroate synthase (dhps) gene at codons 436, 437, 540 and 581 are associated with resistance to sulfadoxine.^{8,9} Additional mutation at the dhfr codon 164, which is isoleucine to leucine (I164L), provides high-level resistance against pyrimethamine, mostly found in the parasites in Southeast Asia¹⁰ and Latin America.¹¹ However, few studies

Correspondence: Olusola Ojurongbe, Department of Medical Microbiology and Parasitology, Ladoke Akintola University of Technology, P.M.B 4400, Osogbo, Nigeria.

Key words: malaria, drug resistance, pregnancy, dhfr.

Conflict of interest: the authors have no conflict of interests.

Acknowledgment: the authors are grateful to all the women who volunteered to participate in the study.

Received for publication: 12 August 2011.

Revision received: 5 October 2011.

Accepted for publication: 30 October 2011.

This work is licensed under a Creative Commons Attribution NonCommercial 3.0 License (CC BY-NC 3.0).

©Copyright O. Ojurongbe et al., 2011
Licensee PAGEPress, Italy
Infectious Disease Reports 2011; 3:e16
doi:10.4081/idr.2011.e16

report the emergence of the I164L mutation in East Africa.^{12,13} The main aim of the present study, therefore, is to assess the prevalence of dhfr mutation in asymptomatic and submicroscopic *P. falciparum* isolates from pregnant women in Nigeria and to explore the possible association of such infection.

Materials and Methods

Study area

The study was carried out in Ilorin, the capital city of Kwara State, located in the middle belt region of Nigeria (lat. 8 30°N, long. 4 30°E) and has a Guinea Savannah type of vegetation. Average daily temperature is 37°C, with a minimum mean temperature of 20°C and maximum mean temperature of 39°C. Average rainfall is about 1,270 mm which falls almost entirely during the wet season from April to October. Patient recruitment took place at the maternity unit of the University of Ilorin Teaching Hospital (UIITH), a tertiary health institution that functions as a teaching hospital.

Study population and recruitment

Pregnant women attending the antenatal clinic participated in the study. Apparently healthy pregnant women were adequately briefed about the purpose and benefits of this study and their consent was obtained before recruitment. Approval for the study was obtained from the UIITH ethical committee.

Sample collection and processing

Finger prick blood sample was collected from each subject for thick and thin blood smears, which were Giemsa stained and checked for *P. falciparum* parasites. The level of parasitemia (parasites/mL blood) was estimated from the results of a leukocyte count and a count of malarial parasites against 200 leukocytes in the thick smear. Two drops of blood were also blotted onto 3 MM Whatman filter paper for molecular studies. All subjects found to be infected were referred to a physician and treated with appropriate artemisinin combination therapy.

Hemoglobin estimation was carried out using photoelectric colorimeter according to Sahli's method, as previously described.¹⁴ Severe anemia was indicated by an Hb concentration of 7.0 g/dL and mild-moderate anemia by an Hb concentration of 7.0-10.5 g/dL. The Hb concentration used as the threshold for anemia was thus reduced from the usual 11.0 g/dL to 10.5 g/dL, to allow for the hemodilution that occurs during pregnancy.¹⁵ The cellulose acetate membrane (CAM) was used to determine the genotype of each patient.¹⁶

Detection of sub-microscopic malaria by PCR

DNA was extracted from the dried blood spots on filter paper using the QIAamp®DNA Mini Kit (Qiagen, Hilden, Germany) following the manufacturer's protocol, and stored at -20°C until further analysis. Stevor gene was used for the detection of submicroscopic malaria as previously described.¹⁷ This gene was chosen because it is a multi-copied gene and we have previously reported that it has a 100% sensitivity and specificity.¹⁷

Detection of DHFR gene mutation

The PCR assays for dhfr mutation included a primary and semi-nested reaction to enhance specificity and sequencing was performed to determine the mutations. In the first reaction, 5.0 µL of DNA extract were amplified in a final volume of 25 µL containing 2.5 µL of reaction buffer, 25mM dNTPs, 0.75 units of Taq DNA polymerase, and 0.5µM of forward and reverse primers. In the first reaction, a 654-basepair (bp) portion of the dhfr gene was amplified by primers DhfrFwd (5'-TTTATATTTCTCCTTTT-TAT-3') and DhfrRvd (5'-ACGCTAACAGA AATAATTGA TACTC-3'). For the second reaction, 3µl of amplified product from the first PCR product was added to the second PCR mixture. Dhfr Fwd2 (5'-TAAGGTTGAAAGC AAAAAT-GAGG-3') and DhfrRvd were used to amplify a 581-bp fragment containing codons 51, 59, 108 and 164. The primers were designed using the Vector NTI Advance™ version 11.0. PCR products were subjected to electrophoresis on 1.5% agarose gels and visualized by transillumina-

tion with ultraviolet light after staining with SYBR® Green. Amplicon sequence was determined using an ABI PRISM 3100 Genetic Analyser (Applied Biosystem). Sequence results were analyzed using the Vector NTI Advance™ version 11.0 software.

Statistical analysis

Statistical analysis was carried out using Graph-pad Instat (Graphpad Software Inc., San Diego, USA). Frequencies were compared using Fisher's exact tests and two sided $P < 0.05$ were considered statistically significant.

Results

A total of 179 pregnant women participated in the study. Their characteristics are shown in Table 1. The overall prevalence of women with *P. falciparum* parasitemia determined by PCR was 41.1% (79/179). Gestational age, parity and blood group did not produce any significant effect on the presence of malaria parasitemia in the study population. Similarly, there was no significant difference between the hemoglobin concentrations of those with or without malaria. Anemia was more common among women with malaria parasitemia but the difference was not statistically significant (Table 1).

Out of the 79 positive cases obtained by stevor PCR, 39 isolates were successfully genotyped for the 3 point mutations on the dhfr gene. The frequency of the point mutations and the combination of the mutations are shown in Table 2. The prevalence of the mutant 108 alleles was 38.5% and 12.8% for N108 and T108, respectively. For the positions 51 and 59, the prevalence of mutant alleles was 64.1% (I51) and 61.5% (R59). The prevalence of the triple mutant alleles (N108 + I51 + R59) in the population was 17.9%. The prevalence of

the triple mutant alleles with respect to number of doses of SP is compared in Table 3. No statistically significant difference was observed between the number of doses and the development of dhfr triple mutation.

Discussion

This study shows the prevalence of the dhfr mutations among parasites obtained from pregnant women with asymptomatic malaria after single or double dose(s) of SP used for IPTp in Nigeria. Dhfr resistant alleles have not yet been well correlated to SP effectiveness in pregnant women. We have previously reported a high prevalence of triple mutant dhfr alleles among children with uncomplicated falciparum malaria suggesting that there is a widespread pyrimethamine resistance in Nigeria.¹⁸ The high prevalence of triple mutant (17.9%) and N108 mutation (38.5%) of the dhfr alleles observed in asymptomatic *P. falciparum* cases may be an indication that SP has a limited duration of usefulness as IPTp in this part of the country. A change from wild-type S108 to N108 has been shown to be adequate to cause low-level pyrimethamine resistance both *in vitro* and *in vivo*. The addition of other mutations (C50 to R50, N51 to I51, and C59 to R59) yield a higher level of resistance. Also, more recently, the addition of a mutation at codon 164 (I164 to L164) has been shown to confer the highest level of resistance; although this mutation is not common in African isolates.

The emergence of SP-resistant parasites among pregnant women in Nigeria could be explained in part by previous pyrimethamine chemoprophylaxis usage. Weekly dose of pyrimethamine monotherapy was previously commonly used among pregnant women for prevention of malaria in pregnancy in Nigeria^{19,20} and a recent survey (RL Opatokun,

Table 1. Characteristics of the pregnant women with and without submicroscopic *P. falciparum* infection in Ilorin, Nigeria.

Characteristics		With malaria parasite N = 79	Without malaria parasite N = 100	P
Gestational age	Mean age ± SD	28.3±5.04	29.1±5.16	0.192
	2 nd trimester	43 (54.4%)	64 (64.0%)	0.195
	3 rd trimester	36 (45.6%)	36 (36.0%)	
Parity	Primigravide	36 (46.6%)	51 (51.0%)	0.470
	Multigravide	43 (54.4%)	49 (54.4%)	
Blood group	A	27 (34.2%)	45 (45%)	0.221
	AB	5 (6.3%)	2 (2%)	
	B	14 (17.7%)	13 (13%)	
	O+	32 (40.5%)	40 (40%)	
	O-	1 (1.3%)	0 (0.0%)	
Mean hemoglobin		11.2±1.46	11.4± 1.37	0.347
Anemia		23 (29.1%)	23 (23%)	0.354

Table 2. Prevalence of dhfr mutations in *P. falciparum* isolates obtained from pregnant women in Ilorin, Nigeria.

Gene	Amino Acid Wild/Mutant	N = 39 Wild	Mutant	Mixed
51	N/I	10 (25.6%)	25 (64.1%)	4 (10.3%)
59	C/R	13 (33.3%)	24 (61.5%)	2 (5.1%)
108	S/N S/T	19 (48.7%)	15 (38.5%) 5 (12.8%)	0
164	I/L	40 (100%)	0	0
51 + 59		13 (33.3%)	26 (66.7%)	0
51 + 108		3 (7.7%)	10 (25.6%)	26 (66.7%)
59 + 108		1 (2.6%)	7 (17.9%)	31 (79.5%)
51 + 59 + 108		0 (37.5%)	7 (17.9%)	32 (82.1%)

Table 3. The effect of number of doses of SP on the presence of triple dhfr mutation.

SP Dose	N.	Dhfr triple mutation	P
1 dose	25	5 (20%)	
> 1 dose	14	2 (14%)	1.0000
Total	39	7 (17.9%)	

unpublished data, 2011) in Osogbo, South Western Nigeria the country showed that over 10% of pregnant women are still using Daraprim®, a weekly pyrimethamine monotherapy for malaria prevention. Current IPT-SP treatment and previous pyrimethamine monotherapy in pregnant women could have caused bias by selecting resistant parasites on an individual basis and successively over time. An earlier study in Tanzania showed that pyrimethamine chemoprophylaxis in children was paralleled by a rapid emergence and worsening of drug resistance, arguing against the use of pyrimethamine as a monosubstance.⁸ In this study, we did not observe a significant difference in the prevalence of triple dhfr mutant alleles between women that took a single dose compared to those who took 2 or 3 doses. One limitation of this study was that the drugs were not taken under the supervision of the physician. The women were given the drugs freely to take home and the compliance of the women cannot be independently verified.

The prevalence of asymptomatic malaria in our study area is 44%. Variable prevalence of malaria ranging from low (7.7%),²¹ to high (75%)²² has been reported among pregnant women in Nigeria. Agomo *et al.*²¹ attributed these differences in the reported prevalence rates to the skill and experience of the laboratory personnel involved in blood film preparation, staining, and reading of the slides. In our study, we relied on PCR for the true prevalence of asymptomatic malaria in the study population. PCR-based assays remain the most sensitive and specific methods for the detection of malaria parasites.¹⁷

Although anemia was more common among

pregnant women who had malaria parasite compared to those who did not, the difference was not significant. One explanation for this observation could be because most of the malaria positive pregnant women had low density and submicroscopic parasitemia. Thus, these parasites are unlikely to have contributed significantly to the presence of anemia in this study population.

In conclusion, we report a high prevalence of dhfr gene mutations in submicroscopic falciparum parasite obtained from pregnant women in Nigeria. Replacement of SP by an alternative drug will be necessary in the near future for successful implementation of IPTp. Regular assessment of sulfadoxine/pyrimethamine and its correlation to molecular markers in pregnant women is also recommended.

References

1. Steketee RW, Wirima JJ, Campbell CC. Developing effective strategies for malaria prevention programs for pregnant African women. *Am J Trop Med Hyg* 1996;55:95-100.
2. WHO. A strategic framework for malaria prevention and control during pregnancy in the African region. Brazzaville, Republic of Congo, 2004.
3. Mubyazi G, Bloch P, Kamugisha M, et al. Intermittent preventive treatment of malaria during pregnancy: a qualitative study of knowledge, attitudes and practices of district health managers, antenatal care staff and pregnant women in

Korogwe District, North-Eastern Tanzania. *Malar J* 2005;4:31.

4. Falade CO, Yusuf BO, Fadero FF, et al. Intermittent preventive treatment with sulphadoxine-pyrimethamine is effective in preventing maternal and placental malaria in Ibadan, south-western Nigeria. *Malar J* 2007;6:88.
5. FMOH. National guidelines and strategies for malaria prevention and control during pregnancy. A publication of the Federal Ministry of Health, Nigeria. Abuja Nigeria.
6. Aziken ME, Akubuo KK, Gharoro EP. Efficacy of intermittent preventive treatment with sulfadoxine-pyrimethamine on placental parasitemia in pregnant women in midwestern Nigeria. *Int J Gynaecol Obstet* 2011;112:30-3.
7. Oyibo WA, Agomo CO. Scaling up of intermittent preventive treatment of malaria in pregnancy using sulphadoxine-pyrimethamine: prospects and challenges. *Matern Child Health J* 2011;15:542-52.
8. Gregson A, Plowe CV. Mechanisms of resistance of malaria parasites to antiparasites. *Pharmacol Rev* 2005;57:117-45.
9. Nzila AM, Mberu EK, Sulo J, Dayo H, et al. Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in *Plasmodium falciparum*: genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites. *Antimicrob Agents Chemother* 2000;44:991-6.
10. Biswas S, Escalante A, Chaiyaroj S, et al. Prevalence of point mutations in the dihydrofolate reductase and dihydropteroate synthetase genes of *Plasmodium falciparum* isolates from India and Thailand: a molecular epidemiologic study. *Trop Med Int Health* 2000;5:737-43.
11. Plowe CV, Cortese JF, Djimde A, et al. Mutations in *Plasmodium falciparum* dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. *J Infect Dis* 1997;176:1590-6.
12. Alker AP, Mwapasa V, Purfield A, et al. Mutations associated with sulfadoxine-pyrimethamine and chlorproguanil resistance in *Plasmodium falciparum* isolates from Blantyre, Malawi. *Antimicrob Agents Chemother* 2005;49:3919-21.
13. Kiara SM, Okombo J, Masseno V, et al. In vitro activity of antifolate and polymorphism in dihydrofolate reductase of *Plasmodium falciparum* isolates from the Kenyan coast: emergence of parasites with Ile-164-Leu mutation. *Antimicrob Agents Chemother* 2009;53:3793-8.
14. Barduagni P, Ahmed AS, Curtale F, et al. Performance of Sahli and colour scale methods in diagnosing anaemia among

- school children in low prevalence areas. *Trop Med Int Health* 2003;8:615-8.
15. Alusala DN, Estambale BB, Magnussen P, et al. Predictors of serum ferritin and haemoglobin during pregnancy, in a malaria-endemic area of western Kenya. *Ann Trop Med Parasitol* 2008;102:297-308.
16. Wild BJ, Bain BJ. Detection and quantitation of normal and variant haemoglobins: an analytical review. *Ann Clin Biochem* 2004;41:355-69.
17. Oyedeji SI, Awobode HO, Monday GC, et al. Comparison of PCR-based detection of *Plasmodium falciparum* infections based on single and multicopy genes. *Malar J* 2007;6:112.
18. Ojurongbe O, Oyedeji SI, Oyibo WA, et al. Molecular surveillance of drug-resistant *Plasmodium falciparum* in two distinct geographical areas of Nigeria. *Wien Klin Wochenschr* 2010;122:681-5.
19. Fawole AO, Onyeaso NC. Perception and practice of malaria prophylaxis in pregnancy among primary health care providers in Ibadan, Nigeria. *West Afr J Med* 2008;27:92-6.
20. Yusuf OB, Dada-Adegbola HO, Ajayi IO, Falade CO. Malaria prevention practices among mothers delivering in an urban hospital in southwest Nigeria. *J Vector Borne Dis* 2008;45:217-24.
21. Agomo CO, Oyibo WA, Anorlu RI, Agomo PU. Prevalence of malaria in pregnant women in Lagos, South-West Nigeria. *Korean J Parasitol* 2009;47:179-83.
22. Adefioye OA, Adeyeba OA, Hassan WO, Oyeniran OA. Prevalence of malaria parasite infection among pregnant women in Osogbo, southwest, Nigeria. *American-Eurasian J Sci Res* 2007;2:43-5.

Non-commercial use only